An Overview of Clinical Trials on the Duration of Dual Antiplatelet Therapy and the Scope of Novel Oral Anticoagulants Following Percutaneous Coronary Intervention

Author:

Singh Ambukeshwar1,Gupta Alka1,Sharma Jayesh1,Anand Vishal1,Narain Varun Shankar1

Affiliation:

1. Department of Cardiology, Divine Heart and Multispeciality Hospital, Lucknow, Uttar Pradesh, India

Abstract

ABSTRACT After percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) is an important therapy for preventing thrombotic events. Numerous clinical trials have been conducted to determine the ideal length of therapy in relation to the duration of DAPT. Similar to this, various clinical trials have investigated the use of novel oral anticoagulant (NOAC) medication in conjunction with DAPT following PCI. In this review, we sum up the findings from various significant clinical studies that have influenced the duration of DAPT and the scope of NOAC therapy following PCI.

Publisher

Medknow

Reference44 articles.

1. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease:A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines:An update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery;Levine;Circulation,2016

2. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS:The task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS);Valgimigli;Eur Heart J,2018

3. Novel oral anticoagulants following percutaneous coronary intervention;Abadie;Circ Cardiovasc Interv,2020

4. Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents:A systematic review and network meta-analysis;Khan;Circulation,2020

5. Extended duration of dual-antiplatelet therapy after percutaneous coronary intervention:How long is too long?;Howard;J Am Heart Assoc,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3